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B Cell Responses to a Peptide Epitope. VII. Antigen-Dependent
Modulation of the Germinal Center Reaction
Anshu Agarwal, Bishnu P. Nayak, and Kanury V. S. Rao1
Germinal center responses to two analogous peptides, PS1CT3 and G32CT3, that differ in sequence only at one position within
the B cell epitopic region were examined. In comparison with peptide PS1CT3, peptide G32CT3 elicited a poor germinal center
response. By demonstrating equal facility of immune complexes with IgM and IgG Ab isotypes to seed germinal centers, we
excluded differences in isotype profiles of early primary anti-PS1CT3 and anti-G32CT3 Ig as the probable cause. Quantitative
differences in germinal center responses to the two peptides were also not due to either qualitative/quantitative differences in T
cell priming or variation in the frequency of the early Ag-activated B cells induced. Rather, they resulted from qualitative
differences in the nature of B cells primed. Analysis of early primary anti-PS1CT3 and anti-G32CT3 IgMs revealed that the latter
population was of a distinctly lower affinity, implying the existence of an Ag affinity threshold that restricts germinal center
recruitment of G32CT3-specific B cells. The impediment in anti-G32CT3 germinal center initiation could be overcome by making
available an excess of Ag-activated Th cells at the time of immunization. This resulted in the appearance of a higher affinity
population of G32CT3-specific B cells that, presumably, are now capable of seeding germinal centers. These data suggest that the
strength of a germinal center reaction generated is Ag dependent. At least one regulatory parameter represents the quality of B
cells that are initially primed. The Journal of Immunology, 1998, 161: 5832–5841.
I t is generally believed that T-dependent Ag-induced activa-tion of B cells first occurs in the T cell-rich extrafollicularsites. Shortly thereafter, foci of specific Ab-producing B cells
(AFCs)2 concentrate in the periphery, adjacent to the red pulp, of
the periarteriolar lymphoid sheath (PALS) (1). Within the next few
days, germinal centers (GCs) can be observed to develop within
the primary B cell follicles, where processes related to affinity
maturation and B lymphocyte differentiation into either memory or
plasmacytes are initiated (1–9).
A consensus view has emerged in the literature to account for
the relationship between AFCs in the outer PALS and GCs during
a primary T-dependent humoral response. The identification of
clonal relatedness between cells that seed developing GCs and
those within AFCs has led to the proposition that constituents of
both compartments derive from a common precursor (10). As a
result, it is generally believed that a subset of B cells activated in
the T cell areas to form AFC also migrate into the primary follicle
to initiate GC development (4). Seeding of GCs is thought to be
driven by deposition of immune complexes of Ag with Ab secreted
in the foci onto follicular dendritic cells (FDCs) (1–9). Although
this has found general acceptance, there are, however, data in the
literature that highlight inconsistencies with the overall scheme.
For instance, Klinman’s group has provided evidence to suggest
that B cells that nucleate early AFCs and GC reactions derive from
distinct lineages and independently give rise to primary Ab and
memory B cell responses (11–13). These populations were phe-
notypically distinguished on the basis of either high or low levels
of expression of the surface marker J11D (11). It was further dem-
onstrated that only the J11Dlow subpopulation of B cells was ca-
pable of originating GCs (12). Recent studies also question the
criticality of AFC formation as a prerequisite to induction of GCs.
Thus, for example, a primary murine humoral response to vesic-
ular stomatitis virus was found to occur in the absence of any
detectable virus-specific AFCs, although specific GCs could
readily be identified (14). More recently, Vora et al. (15) were
unable to observe AFC formation in an antiarsonate response in
A/J mice despite the occurrence of a vigorous GC response. It has
been suggested from these studies that there are intrinsic differ-
ences in the nature of B cell clones that participate in the AFC and
GC responses (15).
Regardless of whether phenotypic distinctions do, in fact, exist,
it is, nevertheless, clear that there is some degree of differentiation
between B cells that populate GCs and those that constitute AFCs.
A variety of studies have observed that the overall clonal hetero-
geneity of GC B cells is markedly diminished compared with those
initiated in the PALS (1–10). In other words, not all B cells acti-
vated by Ag in the PALS are eventually successful in seeding GCs.
These findings clearly point toward the involvement of a selection
mechanism(s) that filters the candidates vying for accommodation
within the GC pathway. Processes that guide such a selection and
parameters that enforce this discrimination, however, remain to be
elucidated.
We have been using synthetic peptides as model Ags in an effort
toward delineating clonal selection mechanisms that regulate an
early primary T-dependent humoral response (16–20). In a recent
report we employed a pair of analogous peptides, PS1CT3 and
G32CT3, which differed in sequence only at a single amino acid
residue position (19). Although both peptides were equally com-
petent at priming T cells in vivo, the primary humoral response to
peptide G32CT3 was markedly reduced compared with that
against peptide PS1CT3 (19). In the present report we exploited
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these differences to examine Ag-dependent modulation of GC re-
sponses, with particular emphasis on the role of Ag-activated B
cells. We show here that the intensity of a GC reaction obtained is
dependent on Ag and, more specifically, on the quality of B cells
that are initially activated. Further, our results suggest that an Ag-
affinity barrier exists that enforces the selection of a limited spec-
trum of B cell clones for seeding the GC reaction.
Materials and Methods
Materials
HRPO-labeled secondary Abs were obtained from Sigma (St. Louis, MO).
Coated magnetic beads for panning of B and T cells (Dynabeads, mouse
pan T and mouse pan B) were purchased from Dynal (Oslo, Norway).
Derivatized amino acids for peptide synthesis were procured from Nova-
biochem (Laufelfingen, Switzerland). Biotinylated PNA, streptavidin-alka-
line phosphatasem and streptavidin-HRPO conjugates were obtained from
Vector (Burlingame, CA), and anti-B7-2 (clone GL1) was purchased from
PharMingen (San Diego, CA).
Peptide synthesis
Peptides were synthesized on a Milligen 9050 synthesizer (Millipore, Bed-
ford, MA) using F-moc chemistry (21). Crude peptides were purified to
.95% purity by reverse phase HPLC on a C18 column (15 mm; dPAk,
Waters, Milord, MA; 19 3 300 mm) using an aqueous gradient of 0–70%
acetonitrile in 0.1% TFA. The identities of all peptides were ascertained by
both amino acid analysis and mass spectrometry.
For synthesis of Tet-PS1 and Tet-G32 peptides the following scheme
was employed. A protected cysteine was first added to the solid support, to
which was then coupled a lysine that was differentially protected at the
e-amino group with a t-butoxycarbonyl functionality and with F-moc at the
a-amino group. After selective F-moc deprotection, a second lysine was
coupled, but both the amino groups were derivatized with F-moc. F-moc
deprotection of this lysine then yielded two reactive amino functionalities
on which either the PS1 or the G32 sequence was sequentially built using
the standard procedures. After completion of synthesis the amino-terminus
was acetylated, and subsequent cleavage from solid support yielded a pep-
tide containing two copies of either the PS1 or the G32 sequence. Air
oxidation resulted in dimerization through disulfide bond formation at the
carboxyl-terminal cysteines to generate a single molecule with four copies
of the epitope sequence. Subsequent biotinylation with NHS-LC-biotin
(Pierce, Rockford, IL) at the e-amino group of the penultimate lysine
yielded the peptides Tet-PS1 and Tet-G32 (Fig. 1B). The remaining pro-
cedure was as described above.
Animals and immunizations
Female BALB/c mice (6–8 wk old) were obtained from the small animal
breeding facility at the National Institute of Nutrition (Hyderabad, India).
Except where stated, immunizations were generally given i.p. at a dose of
50 mg/mouse as an emulsion in CFA. For polyclonal sera, mice were bled
from the retro-orbital plexus, and sera within a group were usually pooled.
For CT3 prepriming, mice were immunized with 50 mg/mouse of a CFA
emulsion of peptide CT3 (at the base of the tail) 7 days before immuni-
zation with either peptide PS1CT3 or G32CT3.
Ab isotype separation and generation of immune complexes
Immune sera collected at various time points were individually resolved for
the IgM and IgG components by passing over a protein G-Sepharose col-
umn (Pharmacia, Uppsala, Sweden). The flow-through contained IgM,
whereas bound IgG, after thorough washing of the column, was eluted with
glycine-HCl buffer, pH 2.7. The eluate was immediately neutralized, con-
centrated, and then dialyzed against PBS before use. Both verification of
the absence of the unwanted isotype and estimation of Ag-specific IgG and
IgM were determined by quantitative ELISA.
For preparation of immune complexes, IgM, IgG, or total Ig prepara-
tions were incubated with a 10-fold excess of peptide (based on the esti-
mated number of specific binding sites) in PBS for 1 h at 37°C with oc-
casional shaking. The preparation was then dialyzed against PBS (three
changes over 4 h) to remove unbound peptide and concentrated if neces-
sary. Aliquots of 100 ml containing immune complexes corresponding to
500 ng of starting Ab were injected i.v. into recipients. We first established,
in pilot experiments, that this was the optimum Ab concentration for use in
GC reconstitution experiments.
Enrichment of B and T cells from immunized mice
After depletion of RBCs (RBC lysis buffer, Sigma) either splenocytes (for
B cells) or inguinal lymph node cells (for T cells) were first separated from
adherent cells by two rounds (1 h each at 37°C) of panning on plastic
plates. For enriched B cells, the resulting splenocyte suspension was de-
pleted of T cells by two rounds of treatment with anti-Thy1.2-coated mag-
netic beads (Dynal). On the other hand, for enriched T cells, lymph node
cells were deprived of B cells by two rounds of treatment with anti-B220-
coated magnetic beads (Dynal). The remaining cell suspension was pel-
leted and resuspended in culture medium (RPMI 1640) to the appropriate
cell concentration. By these procedures a cell purity between 90–95% was
obtained as determined by a FACS analysis, with contaminating lympho-
cytes (i.e., either B or T cells) representing between 2–4% of the total
population. Cell viability was determined by trypan blue exclusion.
Reconstitution of GCs in vivo
A total volume of 200 ml containing immune complexes of 500 ng of Ab
and 5 3 106 enriched T cells from mice primed with CT3 10 days earlier
and then boosted after 1 wk was transferred (i.v.) into irradiated (550 rad)
BALB/c mice. Twenty-four hours later these mice also received (i.v.) en-
riched B cells (1 3 107 in 200 ml/mouse) derived from splenocytes of mice
immunized 2 days earlier with the appropriate peptide (i.e., PS1CT3 or
G32CT3). Ten days after B cell transfer, spleens were removed from the
irradiated hosts, and sections prepared for detection and enumeration of
Ag-specific GCs. These conditions were optimized after a series of pilot
experiments.
Immunohistochemical staining of Ag-specific GCs
Six-micron-thick sections of frozen spleens were taken on a cryostat mi-
crotome and thaw-mounted on glass slides. Sections were allowed to dry
briefly, after which they were fixed in ice-cold acetone for 10 min, air-dried
for 10 min, and stored at 270°C until use.
When required, the frozen sections were thawed and rehydrated in PBS
for 20 min. Endogenous peroxidase activity was quenched with 0.1% phe-
nylhydrazine (Sigma). After three washes, sections were blocked for non-
specific binding with a 1/1 (v/v) solution of 3% BSA (in PBS) and mouse
nonimmune serum for 1 h at 37°C. Slides were then incubated for 90 min
with 20 mg/ml of PNA-biotin in HEPES (pH 7.5) and washed, followed by
a second incubation with streptavidin-HRPO (5 mg/ml in PBS) for 45 min.
Both incubations were performed at 37°C. Subsequent to this either Tet-
PS1 or Tet-G32 was added in PBS at a concentration of 50 mg/ml, and the
slides were incubated overnight at 4°C. After a wash the slides were treated
with the recommended concentrations of streptavidin-alkaline phosphate
conjugate in PBS for 45 min at 37°C. Bound conjugates were then visu-
alized in a sequential manner. The HRPO conjugate was first detected by
color development with the 3-amino-9-ethylcarbazole (AEC) staining kit
(Vector), where a red color for PNA1 cells was obtained. Bound alkaline
FIGURE 1. Model peptide immunogens PS1CT3 and G32CT3. A
shows the amino acid sequence of the parent peptide PS1CT3 and its an-
alogue G32CT3 in the single letter code for amino acids (for details see
text). In peptide G32CT3, the proline residue at position 5 has been sub-
stituted with a glycine residue. The two glycine-residue spacer at position
16 and 17 has been underlined. B depicts the peptide Tet-PS1, a biotinyl-
ated peptide containing the PS1 sequence in a tetrameric configuration. The
double bond between the cysteines is meant to indicate a disulfide bond
(see Materials and Methods). In the corresponding analogue Tet-G32, the
proline residue within the PS1 sequence (indicated by a star) was replaced
with glycine. Note that each molecule contains four copies of the B epitope
sequence and two units of biotin.
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phosphatase was revealed with the blue staining kit (Vector), which de-
tected the presence of Ag-specific cells. A minimum of 30 individual sec-
tions, spread longitudinally across the spleen, were examined from each
spleen, and each experimental group included from three to five mice.
ELISAs
Plates were coated with 2 mg/ml of peptide/well in 100 ml of PBS (pH 7.2)
at 37°C for 3.5 h. Subsequently, they were blocked with 300 ml/well of a
5% solution of fat-free dry milk powder in PBS at 37°C for 1 h. Then, 100
ml of the appropriate dilution of mouse antiserum was added and incubated
at 37°C for 1 h. After washing, bound Ab was detected with HRPO-labeled
secondary Ab (37°C, 1 h), followed by color development with o-phenyl-
enediamine as chromogen. Absorbance was measured at 490 nm, and back-
ground absorbance obtained for preimmune serum at the corresponding
dilution was subtracted.
For competitive ELISA experiments, antisera were used at dilutions
representing 50% of the titer value. Twofold higher concentrations of an-
tiserum and competitor peptide were mixed in equal volumes and incu-
bated for 10 min at room temperature. This was then added to duplicate
wells at 100 ml/well. The rest of the procedure was performed as described
above.
ELISPOT assays
Twenty-four well culture plates (Nunc) were coated with 1 ml of a 20
mg/ml solution of either peptide PS1CT3 or peptide G32CT3 in PBS at 4°C
overnight. Nonspecific sites were then blocked with 0.5 ml/well of a 1%
solution of BSA in PBS at 37°C for 1 h. Splenocytes from mice immunized
with either peptide PS1CT3 or G32CT3 were removed at appropriate times
and depleted of RBCs and adherent cells as described above. These were
then suspended in RPMI 1640 medium at varying dilutions of 1 3 107, 1 3
106, and 1 3 105 cells/ml of viable cells. Of this, 1-ml aliquots were added
to quintuplet wells, and the plates were incubated at 37°C for 2 h. After this
the wells were washed (three times) and then incubated with the appropri-
ate dilution of a mixture of anti-mouse IgM and anti-mouse IgG conjugated
to alkaline phosphatase at 4°C overnight. The plates were then washed
again, and bound conjugate was revealed with 5-bromo-4-chloro-3-indolyl
phosphate in 2-amino-2-methyl-1-propanol buffer. Scoring of spots was
performed under a microscope at 310 magnification.
Results
Peptides PS1CT3 and G32CT3
The model peptide, PS1CT3, that we used in our studies is shown
in Fig. 1A. This peptide represents a chimeric sequence in which
residues 1–15 (segment PS1) correspond to a known B cell epitope
within positions 28–42 of the preS1 region of hepatitis B surface
Ag (22). Residues 18–38 (segment CT3) represent a well-charac-
terized, promiscuous T cell epitope derived from the circumsporo-
zoite protein of the malaria parasite Plasmodium falciparum (23).
Separating the B and T cell epitopes is a spacer of two glycine
residues at positions 16 and 17, which have been included for
reasons described previously (24). Peptide G32CT3 represents a
single amino acid-substituted analogue of peptide PS1CT3 in
which the proline at position 5 has been replaced with a glycine
residue (Fig. 1A).
In our previous studies we have shown in mice that while the
early IgM response to peptide PS1CT3 includes Ab specificities
that cumulatively recognized the entire PS1 segment, a subsequent
class switch was restricted to B cell specificities directed only
against the tetrapeptide sequence positions 4–7 (sequence DPAF)
(17). Interestingly, as described previously (19), immunodomi-
nance of the DPAF segment was independent of a variety of vari-
ables that included the H-2 haplotype of the mouse strain em-
ployed. Further, the Ab repertoire elicited against the epitope was
also heterogeneous; it was composed of Abs containing a variety
of VH and VL gene segments with diverse CDR3 lengths and com-
position (25). More recently we have demonstrated that a single
amino acid substitution within this sequence (proline to glycine,
peptide G32CT3) was sufficient to render the resultant analogue
virtually nonimmunogenic (19). While immunization with both
peptides PS1CT3 and G32CT3 yielded comparable levels of early
primary IgM Abs, the anti-G32CT3 response was aborted, in that
neither class switch of Abs from IgM to the IgG isotype or of B
cell differentiation into a memory population was detected (19).
This was particularly surprising considering that peptide G32CT3
was shown to be as potent as peptide PS1CT3 at priming T cells
in vivo (19). This enigma was subsequently resolved by our dem-
onstration of a higher T-dependent activation threshold for the step
coinciding with Ab isotype switch, where the affinity of B cell sIg
receptor of a given B cell clonotype for Ag proved the deciding
factor between positive selection and elimination at this stage (19).
For reasons presently unclear, the early Abs generated against peptide
G32CT3, in contrast to the anti-DPAF component in PS1CT3, proved
to be of too low an affinity to permit successful cross-over (19).
From our description above, it is obvious that peptides PS1CT3
and G32CT3 represent analogous immunogens that, although iden-
tical with respect to induction of T cell responses, significantly
differ at the level of the B cell responses elicited. Thus, these
peptides provided us with a good model system to evaluate a pos-
sible role for distinctions in primary B cell activation in the effi-
ciency of GC formation. We recall here that both peptides PS1CT3
and G32CT3 have previously been shown to represent T-depen-
dent Ags, even at the level of early primary IgM Ab induction (17).
Immunization with peptide G32CT3 elicits a poor GC response
To evaluate any differences in GC responses against the two an-
alogue peptides, parallel groups of BALB/c mice were immunized
with peptide PS1CT3 or peptide G32CT3. Subsequently, spleens
were removed at various time points, and sections thus obtained
were stained for the immunohistochemical detection of Ag-spe-
cific GCs. A double-staining protocol for B cells that were both Ag
specific and PNA1 was employed (see Materials and Methods).
For the detection of Ag-specific B cells, a separate, biotinylated
peptide containing only the B cell epitope segment (PS1 or G32),
but in a tetrameric configuration, was designed and synthesized
(peptides Tet-PS1 and Tet-G32; Fig. 1B). In preliminary experi-
ments we observed that such a peptide provided for a higher in-
tensity of staining, as opposed to a biotinylated monomer, presum-
ably by increasing the avidity of binding to B cells (data not
shown).
Fig. 2 depicts a representative staining obtained for GCs induced
in mice immunized 7 days earlier with peptide PS1CT3. The ki-
netics of GC formation against PS1CT3 are shown in Fig. 3. GCs
were first evident on day 6 and rapidly increased in number up to
day 10, after which their number began to decline (Fig. 3). Sur-
prisingly, in contrast to peptide PS1CT3, peptide G32CT3 induced
only a marginal GC response, which was also transient (Fig. 3).
Since both peptides are known to prime T cells equally well (19),
it follows then that the differences shown in Fig. 3 are likely to be
a result of distinctions in the B cells that have been activated by the
two immunogens.
We have shown earlier that the defect in an anti-G32CT3-primed
humoral response could be overcome by prepriming the mice with a
peptide (peptide CT3) representing the T cell epitope segment (seg-
ment CT3) of the immunogen molecules (19). In other words the
constraint imposed by the low affinity, for Ag, of G32CT3-activated
B cells could be circumvented by increasing the frequency of avail-
able Ag-primed Th cells. To determine whether such a strategy may
also ameliorate GC induction, a parallel cohort of mice was first pre-
primed with peptide CT3 before immunization with peptide G32CT3.
As shown in Fig. 3, CT3 prepriming clearly resulted in a vigorous and
sustained anti-G32CT3 GC reaction that was even more pronounced
than that obtained against peptide PS1CT3. In contrast, administration
of peptide CT3 2 days after primary immunization with peptide
G32CT3 (day 0) did not result in any significant improvement in the
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number of GCs detected on day 7 (data not shown). Thus, the inad-
equacy of G32CT3-primed B cells to initiate a GC reaction could be
circumvented by increasing the pool size of available Ag-activated T
cells, which appear to be required in the very early stages of a primary
anti-G32CT3 humoral response.
Although we have suggested that the positive effect of CT3
prepriming derives from an increased frequency of Ag-activated T
cells, the possibility of differential ability of memory vs primary
activated T cells in supporting development of G32CT3-specific
GCs cannot be ignored at present.
Immune complexes with both IgM and IgG Abs are equally
proficient at supporting GC formation
It was possible that the observed differences in the GC response to
the two peptides could be due to the absence of an IgM to IgG Ab
class switch in the peptide G32CT3-immunized mice (19). There
is some variance in the literature regarding the relative abilities of
immune complexes generated with IgG or IgM Abs to seed GCs.
While earlier reports suggested that only the IgG-constituted im-
mune complexes are functional (26), more recent studies have
demonstrated the presence of IgM-constituted immune complexes
on FDCs within active GCs (1). Nevertheless, given the uncer-
tainty, a formal possibility remained that immune complexes with
the IgG isotype of Ab are more efficient at promoting GC forma-
tion, thereby explaining the marginal number of GCs obtained in
the anti-G32CT3 response. Consequently, by inducing an anti-
G32CT3 IgM to IgG class switch (19), CT3 prepriming would be
expected to restore GC initiation.
To examine any potential differences between immune com-
plexes with either IgG or IgM Abs, we performed in vivo GC
reconstitution experiments using peptide PS1CT3 as the test sys-
tem. For this, irradiated BALB/c mice (550 rad) were adoptively
transferred with enriched T cells from CT3-primed mice and im-
mune complexes of peptide PS1CT3 with day 7 anti-PS1CT3
FIGURE 2. Identification of peptide
PS1CT3-specific GCs by immunohistochemical
staining of spleen sections. For experimental de-
tails refer to Materials and Methods. Shown is a
3100 magnification of a representative spleen
section, double stained for Ag-specific (Tet-PS1)
and PNA1 B cells. PNA positivity is revealed by
the red color, whereas Ag-specific cells stained
blue. A depicts a peptide PS1CT3-specific GC.
Specificity of Ag staining is revealed by com-
parison with B, which shows a GC from the
same spleen, but negative for Tet-PS1 reactivity.
In addition, GCs in splenic sections from mice
mock immunized with CFA alone or those
immunized with keyhole limpet hemocyanin
(KLH) also did not stain with peptide Tet-PS1.
FIGURE 3. Ag-dependent modulation of GC
responses. For the data in A, groups of four mice
each, immunized with either peptide PS1CT3 (F)
or G32CT3 (E), were sacrificed at the indicated
time points, spleens were removed, and sections
were processed for the immunohistochemical de-
tection peptide-specific GCs using either Tet-PS1
or Tet-G32 as appropriate (see Materials and
Methods). An additional group of mice was first
preprimed with peptide CT3 (50 mg/mouse in
CFA, base of tail, day 27) followed by immuni-
zation (day 0) with peptide G32CT3 (D). At least
30 dispersed sections were examined per spleen,
and the data in A are presented as the number of
GC (6SD) averaged over 10 sections. The nega-
tive controls described for Fig. 2 were also in-
cluded here. The results are representative of four
independent experiments. B and C show represen-
tative staining for Ag-specific GCs (magnification,
325), as described in Materials and Methods, for
spleen sections obtained on day 10 from mice im-
munized with either peptide PS1CT3 (B) or pep-
tide G32CT3 (C). While GCs that stain intensely
for Ag are evident in sections from PS1CT3-im-
munized mice, they are absent in those from
G32CT3-immunized mice.
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polyclonal antiserum purified for either IgM or IgG Abs (see Ma-
terials and Methods). Subsequently, the irradiated hosts also re-
ceived enriched B cells from mice immunized 2 days earlier with
peptide PS1CT3. Ten days later, the spleens were removed from
the recipients, and sections were stained for detection of PS1CT3-
specific GCs with peptide Tet-PS1. A representative staining is
shown in Fig. 4, and the cumulative results are given in Table I. As
indicated in Table I, comparable numbers of GCs were obtained
regardless of whether the immune complexes supplied were con-
stituted with the IgG or IgM isotype of Abs. Thus, at least for the
present system, immune complexes generated with both IgG and
IgM Abs appear to be equally proficient at supporting GC forma-
tion. We also extend these results to suggest that the absence of an
IgM to IgG class switch in an anti-G32CT3 response is unlikely to
be the cause of the poor anti-G32CT3 GC reaction that follows.
Differences in GC-initiating abilities are not due to qualitative
differences in T cell priming
Although our earlier results indicated that peptides PS1CT3 and
G32CT3 prime T cells equally well in vivo, it remained possible
that qualitative distinctions in the nature of T cells primed (e.g.,
distribution of fine specificities, TCR repertoire, etc.) could ac-
count for the observed differences in the extent of GC formation
reported here. To verify this we again resorted to the in vivo GC
reconstitution protocol, where enriched B cells from either
PS1CT3- or G32CT3-immunized mice were transferred into irra-
diated hosts followed by enriched T cells derived from mice
primed with peptide CT3. Thus, since both groups here received an
identical primed T cell population, the influence of T cells can be
expected to be normalized. For these experiments the immune
complexes used were prepared from day 7 Ig obtained against the
respective Ags. In addition to these two groups, a third group was
included in which B cells transferred were from CT3-preprimed,
G32CT3-immunized mice.
As evident in Fig. 5, no significant GC formation could be de-
tected in spleens from mice transferred with G32CT3-primed B
cells, whereas an active GC reaction was clearly obtained in the
group receiving PS1CT3-primed B cells. Thus, the possibility of
qualitative differences in the primary anti-PS1CT3 and anti-
G32CT3 T cell responses as a cause of the observed differences in
the magnitude of GC responses can be ruled out. Interestingly,
however, G32CT3-specific B cells from CT3-preprimed mice
proved to be fully competent at reconstituting GCs in irradiated
hosts (Fig. 5). We take this latter result to suggest that the positive
effect, in terms of competency for GC formation, of the availability
of an increased frequency of Ag-activated T cells during the initial
stages of a B cell response is exerted by somehow influencing, at
a presently unknown level, the nature of anti-G32CT3 B cells that
are generated.
Differences in GC-forming abilities are not due to differences in
the frequency of early activated Ag-specific B cells
The observed differences in Figs. 3 and 5 could also be accounted
for by invoking differences in the frequency of Ag-specific B cells
that are initially activated. CT3 prepriming could then function by
increasing such a frequency (or repertoire) by making available an
excess of T cell help. The experiment shown in Fig. 5 employed
Ag-activated B cells only 2 days postimmunization with peptide
G32CT3. Thus, if such a probability were indeed operative, it would
have to represent a very early event that occurs either with or shortly
after Ag-induced activation from the preimmune B cell pool.
FIGURE 4. Both IgM- and IgG-constituted
immune complexes seed GCs. Immune com-
plexes of peptide PS1CT3 with day 7 polyclonal
Ab preparations of either anti-PS1CT3 IgM (A)
or anti-PS1CT3 IgG (B) were separately in-
cluded in in vivo GC reconstitution experiments
along with CT3-primed enriched T cells and
PS1CT3-primed enriched B cells as described in
Materials and Methods. The figure shows the
presence of Ag-specific GCs in splenic sections
derived 10 days later from both groups. A de-
scription of the control groups is included, and
the cumulative results are presented in Table I.
Table I. Immune complexes with either IgM or IgG Ab are equally
supportive of germinal center formation a
Group
Immune
Complexes with Mouse No. GCs/10 Sections
1 IgM 1 39
2 46
3 34
4 36
5 32
2 IgG 1 38
2 76
3 39
4 54
5 42
a GC reconstitution experiments in individual groups of five irradiated mice each
were performed using PS1CT3-immune complexes generated with day 7 polyclonal
antiserum of either the IgM or IgG isotype as described in Materials and Methods.
Spleens were then removed 10 days later, and the resulting sections were stained for
the detection of PS1CT3-specific GCs (Materials and Methods). A minimum of 30
sections, spread longtiudinally across the spleen, were examined per spleen. Data are
expressed as the number of GCs averaged over 10 sections. Control groups included
irradiated mice which received either naive B cells, naive T cells, or enriched B cells
from CFA-mock immunized mice. No GCs could be detected in any of the latter three
groups. Results presented here are from one of three independent experiments.
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We therefore sought, by ELISPOT assays, to compare time-
dependent progression of frequencies of Ab-producing B cells af-
ter primary immunization with the corresponding peptide. The ear-
liest time point taken was at 2 days postimmunization and was
followed up to day 6, at which time the GC reaction was initiated
(see Fig. 3). The results of these experiments are summarized in
Table II. Although low in number, no significant differences in the
number of peptide-reactive spots could be detected in splenocytes
of mice immunized with either peptide PS1CT3 or G32CT3 at 2
days postimmunization (Table II). Such a trend was maintained at
all subsequent time points tested, where the frequency of anti-
G32CT3 Ab-producing B cells was always within twofold that of
Ab against peptide PS1CT3 (Table II). These results are consistent
with our prior observations that the early primary IgM responses
induced by these two Ags are not distinctly different (19). Further,
the data in Table II indicate that the observed difference in the
extent of GC formation is unlikely to have resulted from difference
in the frequency of Ag-activated B cells generated by immuniza-
tion with either peptide PS1CT3 or peptide G32CT3.
To further clarify the influence of Ag-activated B cell frequency,
we again performed GC reconstitution experiments, but with en-
riched B cells from CT3-preprimed mice that had been immunized
2 days earlier with peptide G32CT3. In initial experiments we first
established, by an ELISPOT assay, that the frequency of anti-
peptide Ab-producing B cells in such a population was 45 6 8/1 3
107 cells (mean 6 SD of three independent experiments). Varying
numbers of enriched B cells from CT3-preprimed, G32CT3-im-
munized mice were transferred into irradiated recipients along
with the other components described in Fig. 5. Peptide G32CT3-
specific GCs were then enumerated in sections derived from
spleens removed either 6 or 10 days later, and the results are shown
in Table III. Only marginal differences (within twofold on day 10)
in the extent of GC formation were observed between the various
groups (Table III), suggesting the absence of a significant corre-
lation between the frequency of initially induced Ag-activated B
cells and the number of resulting GCs. It must be noted here that
based on estimates from Table II, the lowest number of enriched B
cells used in Table III would be expected to correspond, in terms
of G32CT3-activated B cells on day 2, to frequencies in the range
of that anticipated for cells from CT3-unprimed, G32CT3-immu-
nized mice. On the other hand, the highest numbers represent those
contained in CT3-preprimed, G32CT3-immunized mice. Thus, it
would appear that poor GC formation in G32CT3-immunized mice
is not a consequence of limiting frequencies of the early Ag-acti-
vated B cells produced.
To further rule out an influence of B cell frequency, purified B
cells from mice immunized 4 days earlier with either peptide
PS1CT3 or G32CT3 were enriched for the Ag-specific subset by
panning against plates coated with the homologous peptide, as
described previously (16). A subsequent FACS analysis, after
staining with either Tet-PS1 or Tet-G32, determined that these
enriched B cell populations contained 3.8 and 2%, respectively,
PS1CT3- and G32CT3-binding cells. These preparations were then
individually diluted with preimmune B cells to achieve a final
concentration of Ag-specific B cells of 4.1 3 104 cells (i.e., at least
40-fold greater than that obtained for PS1CT3-immunized mice on
FIGURE 5. Differences in the extent of GC formation is independent of
any qualitative difference in T cell priming. Groups of five irradiated mice
each were given T cells enriched from mice primed with peptide CT3 7
days earlier and immune complexes generated from day 7 Ig from mice
immunized with peptide G32CT3 (group 1) or PS1CT3 (group 2) or from
mice preprimed (on day 27) with peptide CT3 before immunization (on
day 0) with peptide G32CT3 (group 3). Twenty-four hours later the mice
also received enriched B cells from an independent cohort of mice immu-
nized 2 days earlier either with peptide G32CT3 (group 1) or peptide
PS1CT3 (group 2). Mice in group 3 received enriched B cells from CT3-
preprimed and G32CT3-immunized mice. Ten days later the spleens were
removed for detection and enumeration, in sections, of Ag-specific GCs as
described in Fig. 2. For groups 1 and 3, peptide Tet-G32 was used for
Ag-specific staining, whereas peptide Tet-PS1 was employed for group 2.
Table II. Estimation of Ab-producing B cells in the early immune
response to the peptides a
Immunogen
Days After
Immunization
Spots/1 3 107 Cells
Expt. 1. Expt. 2 Expt. 3.
PS1CT3 2 6.2 6 2.4 6.4 6 1.3 9.0 6 3.8
G32CT3 2 5.4 6 2.7 4.0 6 2.3 3.2 6 1.2
PS1CT3 4 88 6 16 94 6 22 104 6 28
G32CT3 4 64 6 08 68 6 12 62 6 14
PS1CT3 6 85 6 12 113 6 22 110 6 19
G32CT3 6 63 6 06 86 6 07 84 6 11
a Groups of four mice each were either immunized with peptide PS1CT3, G32CT3
or first preprimed with peptide CT3 followed by immunization with peptide G32CT3.
At indicated times, spleens were removed, and peptide-specific Ab producing B cells
were determined in an ELISPOT assay as described in Materials and Methods. Values
for each experiment provided are the mean of those for individual mice in each group
where each determination was performed in quintuplicate.
Table III. Frequency of Ag-activated B cells does not significantly
affect the efficiency of GC formation a
Group
No. of Primed
B Cells
Transferred.
GCs/10 Sections at
Day 6 Day 10
1 None , 1 , 1
2 3 3 105 21 6 8 37 6 6
3 3 3 106 44 6 9 58 6 13
4 3 3 107 51 6 14 73 6 9
a The protocol followed here was as described in Materials and Methods with the
exception that varying numbers, as indicated, of enriched B cells from CT3-preprimed
and G32CT3-immunized mice were taken. Though the number of primed B cells
varied between groups, the total number of enriched B cells transferred, however, was
always kept constant (3 3 107) by making up the difference with enriched B cells
from naive mice. Thus, group 1 in this table received cells that were completely
derived from naive mice (3 3 107). The number of sections screened and data pre-
sentation is as described for Table 1. Data shown are from one of two experiments,
and values are the mean (6SD) of numbers for the four individual mice within each
group.
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day 4; see Table II) before use in GC reconstitution experiments
(see Materials and Methods). Immunohistochemical staining of
splenic sections derived from such hosts 10 days later yielded
64 6 9 and 3 6 2 GCs/10 sections for PS1CT3- and G32CT3-
activated B cells, respectively. Thus, these results along with those
described above categorically rule out quantitative differences in B
cells activated against the two Ags as the causative factor under-
lying the observed differences in the extent of GC formation in
PS1CT3- and G32CT3-immunized mice. In this connection, ear-
lier studies have demonstrated that the available frequency of Ag-
activated immunocytes does not significantly influence either the
extent of GC formation (27) or the eventual output in an immune
response (28).
In separate GC reconstitution experiments, we found that im-
mune complexes with day 7 anti-G32CT3 Ig from CT3-preprimed
mice were unable to initiate GC formation in irradiated mice sup-
plied with G32CT3-activated enriched B cells from mice not prep-
rimed with peptide CT3 (,5 GCs/10 sections). In contrast, im-
mune complexes with day 7 anti-G32CT3 Ig from CT3-unprimed
mice were fully capable of reconstituting GCs from enriched B
cells derived from CT3-preprimed, G32CT3-immunized mice (be-
tween 30–55 GCs/10 sections in a total of five mice). These re-
sults, by ruling out an influence of the nature of early anti-G32CT3
Ig, further reinforce that it is the qualitative difference in anti-G32CT3
B cells generated in the presence or the absence of CT3 prepriming
that accounts for the observed differences in GC formation.
Analysis of early primary serum Abs to peptides PS1CT3 and
G32CT3
We have shown here that it is the immediate to early events fol-
lowing Ag exposure that determine the eventual ability to generate
GCs. Further, our results imply that the discriminatory influence is
exerted at the level of the Ag-activated B cells that are produced.
Given the extremely low frequency of Ab-producing B cells ob-
tained within the first 2 days of peptide G32CT3 immunization, it
was not conceivable for us to probe for differences at that level. We
therefore examined the early primary serum Ab responses under
the various conditions as the next best alternative.
A comparison of the relative avidities of anti-PS1CT3 and anti-
G32CT3 day 7 IgM by competitive inhibition ELISA revealed a
pronounced difference, with anti-G32CT3 IgM displaying a
greater than 25-fold lower avidity than that against peptide
PS1CT3 (Fig. 6A). Prepriming with peptide CT3 had no significant
influence on the IgM response to either peptide (Fig. 6A). Inter-
estingly though, a comparison of the relative avidity of day 7 IgG
proved informative (Fig. 6B). While the relative avidity of anti-
PS1CT3 day 7 IgG either with or without CT3-prepriming was
comparable to that obtained for the corresponding IgM, the anti-
G32CT3 IgG from CT3-preprimed mice was markedly enhanced
over the day 7 anti-G32CT3 IgM (Fig. 6, A and B). The latter result
suggests that CT3-induced IgM to IgG Ab switch in response to
G32CT3 immunization was also accompanied by an improvement
in Ab avidity. We note here that peptide G32CT3 does not induce
an IgG Ab response in the absence of CT3 prepriming (19).
The enhanced avidity of day 7 anti-G32CT3 IgG on CT3 prep-
riming could result from one of two possibilities. First, it may
represent an outcome of affinity maturation processes within GCs
initiated early in response to prepriming with peptide CT3 (Fig. 3).
Alternatively, it may serve as an indicator for either recruitment or
persistence and amplification of a minority population of G32CT3-
specific B cells with a high enough affinity to permit the IgM to
IgG class switch. Our earlier results have shown that a minimum
affinity of early activated B cells for Ag is necessary to undergo an
Ab isotype switch (19). To distinguish between these two possi-
bilities we next monitored the relative avidities of CT3-preprimed,
anti-G32CT3 IgM and IgG as a function of time (Fig. 7). The
earliest time point studied (day 4) was that when the IgG levels
were high enough to obtain reliable data. As shown in Fig. 7, the
distinction between anti-G32CT3 IgM and IgG affinities was evi-
dent very early, even at the stage when significant IgG Ab levels
FIGURE 6. Relative avidities of day 7 polyclonal IgM (A) and IgG (B)
responses to peptides PS1CT3 and G32CT3. Day 7 antisera from individ-
ual mice immunized with either peptide PS1CT3 (E) or peptide G32CT3
(F) were fractionated for IgM and IgG Ab preparations (see Materials and
Methods). Two additional groups were included in which the mice were
first preprimed with peptide CT3 (on day 27) followed by immunization
(on day 0) to yield either day 7 anti-PS1CT3 (D) or day 7 anti-G32CT3 (D)
antisera. The relative avidities of the IgM (A) and IgG (B) fractions were
determined by competitive inhibition ELISA with the indicated concentra-
tions of the homologous immunogen as competitor (see Materials and
Methods). Values are expressed in terms of Ab binding observed at a given
inhibitor concentration as a function of that in the absence of any compet-
itor after subtracting the background observed for preimmune serum. The
data shown are representative of those obtained in a total of 10 mice for
each set, immunized on three separate occasions in groups of three or four
each. Further, the IgM and IgG results given for each immunization set
were derived for fractions from the same antiserum sample. Finally, pep-
tide G32CT3 does not elicit an IgG response unless the mice are first
preprimed with peptide CT3 (19).
FIGURE 7. A time-course analysis of anti-G32CT3 IgM and IgG Abs
in CT3-preprimed mice. Sera from groups of 10 mice each that were CT3
preprimed (on day 27) and then immunized with peptide G32CT3 (day 0)
were collected at the indicated times, pooled within a group, and resolved
for the IgM (F) and IgG (E) fractions. The IC50 values were determined
for each time point by competitive inhibition ELISA as described in Fig. 6.
The data shown are representative of four independent experiments. A
parallel group of CT3-preprimed, G32CT3-immunized mice was simulta-
neously treated with mAb GL1 as previously described (28), and relative
affinities, as IC50 values, were determined for the day 7 IgM (D) and IgG
(D) anti-G32CT3 fractions. These latter results are from one of two sepa-
rate experiments.
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first become detectable. Thereafter, there was no further increment
in the difference, which remained invariant up to day 21 postim-
munization (Fig. 7).
The early differences in anti-G32CT3 IgM vs IgG avidities with
no further enhancement with time suggested that these differences
were unlikely to have resulted from affinity maturation processes
within GCs. Indeed, the absence of an improvement in IgG Ab
affinity with time is not particularly surprising given our recent
observations that primary IgG responses to polypeptide Ags do not
display a significant improvement in affinity over time (P. Nakra
and K. V. S. Rao, unpublished observations). To further verify that
the observed avidity differences are not a consequence of the GC
reaction, we analyzed day 7 sera from CT3-preprimed, G32CT3-
immunized mice that had also been administered mAb GL1, an Ab
specific for the costimulatory molecule B7-2. Treatment with mAb
GL1 has been previously shown to abrogate GC formation in a
primary immune response to the hapten (4-hydroxy-3-nitropheny-
l)acetyl (29). In the present case we first ascertained that admin-
istration of previously suggested (29) doses of mAb GL1 com-
pletely inhibited detectable G32CT3-specific GC formation in
CT3-preprimed mice (data not shown). A determination of day 7
anti-G32CT3 IgM and IgG avidities from such mice yielded values
comparable to those in mAb GL1-untreated mice (Fig. 7). These
results unequivocally confirm that the observed difference in avid-
ity of early primary anti-G32CT3 IgM and IgG Abs originates
from events that are independent of and precede GC formation.
Discussion
While an exhaustive analysis of processes that occur within active
GCs has been conducted by several groups (30–42), events that
regulate its genesis are, at best, sparsely understood. It is now
widely accepted that the primary site of resting B cell activation
upon first exposure to a T-dependent Ag occurs in the T cell-rich
areas of the PALS (43). The products resulting from this initiation
are then thought to locally differentiate into AFC foci in the pe-
riphery of the PALS and also seed adjacent GCs in the lymphoid
follicles (1–10). While prior formation of foci has generally been
considered a prerequisite for GC formation, more recent data have
questioned whether it is obligatory (15). A marked difference in
clonal diversity of cells that seed GCs compared with that of B
cells activated in the foci is also a common characteristic of the
early primary humoral response to T-dependent Ags (1–10). These
differences strongly suggest that not all B cells activated in the
PALS are capable of supporting GC initiation. Consequently, an
understanding of the regulatory processes that guide such a selec-
tion and of the cellular properties that define GC-seeding compe-
tency assumes importance.
Our earlier studies with peptide PS1CT3 and its single amino
acid-substituted analogues (17) fortuitously provided us with a
comparative system to study Ag-dependent modulation of GC re-
sponses. Of particular interest was the analogous peptide G32CT3,
which, although as proficient as the parent peptide PS1CT3 at
priming T cells, elicited a poor B cell response (19). Thus, it
seemed possible to explore the role of Ag-activated B cells in
directing the formation of GCs. The potential utility of our system
was indeed realized in early experiments that revealed that while
peptide PS1CT3 was capable of initiating a robust GC reaction,
those generated in response to peptide G32CT3 immunization
were both drastically curtailed in number and transient in appear-
ance. Their previously demonstrated equipotency at in vivo T cell
priming (19) led us to suspect, prima facie, that these differences
probably arise out of quantitative/qualitative distinctions at the
level of either B cells activated by the respective Ags or the early
Abs produced against them. This inference could be further sub-
stantiated in experiments that also ruled out any qualitative dis-
tinctions in the nature of T cells primed by the two Ags as the
causatory factor.
There exists some degree of equivocality in the literature about
the relative facility of immune complexes constituted by IgM and
IgG isotypes of Abs in supporting initiation of a GC. Although
early studies suggested a selectivity for IgG immune complexes
(28), more recent experiments have demonstrated the presence of
IgM-constituted immune complexes on FDCs within active GCs
(1). In our case, at least with respect to peptide PS1CT3, immune
complexes with polyclonal day 7 anti-PS1CT3 preparations of
both IgG and IgM yielded comparable numbers of GCs. In addi-
tion to implying the absence of a marked preference for either Ab
isotype, we extend these observations to infer that the poor anti-
G32CT3 GC response was unlikely to have been due to the ab-
sence of a m to g class switch in the early primary anti-G32CT3
humoral response. Furthermore, we were unable to explain the
differing extents of GC formation on the basis of differences in the
frequency of early Ag-activated B cells generated in response to
the two Ags.
The poor GC response to peptide G32CT3 immunization could
easily be overcome by the simple expedient of prepriming the mice
with peptide CT3. As described previously (19), CT3 prepriming
functions by increasing the available pool of Ag-activated T cells.
Thus, generation of a productive anti-G32CT3 GC response re-
quired additional T cell help over and above that sufficient for that
against peptide PS1CT3. In addition to confirming prior results
that quantitative differences in T cell help can modulate early Ag-
activated B cell behavior (14, 44), these findings point toward the
conclusion that the level of T cell help required to initiate GC
formation is Ag dependent.
Prepriming with peptide CT3 has been previously shown to
qualitatively influence early anti-G32CT3 Ab production by in-
ducing an IgM to IgG isotype switch (19). However, the results
described here rule out a role for the nature of the early primary Ab
in deciding the facility of GC induction. Immune complexes with
anti-G32CT3 Ig from CT3-preprimed mice were unable to support
GC formation from G32CT3-activated B cells in mice not prep-
rimed with peptide CT3. Conversely, immune complexes with anti-
G32CT3 Ig obtained from CT3-unprimed mice were competent at
supporting GC formation with B cells from CT3-preprimed and
G32CT3-immunized mice. Collectively these results clearly indi-
cate that differences in G32CT3-activated B cells from CT3-
primed vs unprimed mice were responsible for the observed vari-
ations in GC-forming efficiency between the two groups.
Furthermore, our observations that the positive effect of CT3 prep-
riming is abrogated when given 2 days after immunizing with pep-
tide G32CT3 reveals that these distinctions appear early, either
concomitant with Ag exposure or immediately thereafter.
Although the cumulative results from our in vivo GC reconsti-
tution experiments pointed toward a qualitative deficiency in B
cells activated on G32CT3 immunization, we were unable to char-
acterize the nature of this deficiency. The very low frequency of
early anti-G32CT3-activated B cells precluded any direct analysis.
We were, therefore, forced to adopt an empirical approach in
which we examined early primary serum Ab responses under the
various conditions. It was expected that such an analysis could
provide an indirect insight into the nature of the B cells from which
they originate, at least from the standpoint of Ag binding charac-
teristics. Considering that it is also likely to reflect the status of sIg
receptors on B cells that produced them, the pronounced difference
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in the relative avidities of the early primary IgM response to pep-
tides PS1CT3 and G32CT3 was particularly intriguing. It sug-
gested the existence of an Ag affinity threshold that impedes re-
cruitment of G32CT3-activated B cells from CT3-unprimed mice
within GCs. While prior CT3 priming was found to have no in-
fluence on the avidities of anti-PS1CT3 and anti-G32CT3 IgMs, a
surprising selectivity was observed for the early anti-G32CT3 IgG
that resulted. The observed enhancement in the avidity of anti-
G32CT3 IgG over that of the corresponding IgM Abs was in con-
trast to that observed for peptide PS1CT3, for which no significant
difference in avidity could be detected between the two isotype
populations. Although a discriminatory role for early primary Ab
in deciding the efficiency of GC formation was earlier ruled out,
the presence of a novel higher affinity Ab component in the CT3-
preprimed anti-G32CT3 response is also likely to be indicative of
the presence of a high affinity subset in the corresponding Ag-
activated B cell pool. Such a subset is in all probability either
absent in the G32CT3-immunized but not CT3-primed group or
present in numbers too low to be detectable at the level of serum
Ab. Our earlier studies have demonstrated the need for a minimum
affinity of early Ag-activated B cells for Ag to be able to undergo
the IgM to IgG class switch (19). The present data on comparative
avidities of early anti-G32CT3 IgM and IgG, generated in CT3-
preprimed mice, are therefore diagnostic of the facilitation of ei-
ther the existence or the persistence, followed by expansion, of a
higher affinity B cell subset under conditions of CT3 prepriming.
Furthermore, results from a time-course comparison of IgM vs IgG
relative avidities and from mAb GL1-treated mice clearly indicate
that the appearance of the higher affinity subset precedes GC for-
mation and, therefore, may be linked to its etiology. In this con-
nection we have recently observed that G32CT3-activated B cells
from CT3-preprimed mice in in vivo reconstitution experiments
yielded only a marginal GC response when depleted of sIgG1 B
cells by exhaustive panning against anti-mouse IgG (A. Agarwal
and K. V. S. Rao, unpublished observations). This further suggests
a causal correlation between the presence of a high affinity anti-
G32CT3 B cell subset and the efficiency of GC formation.
The presence of a higher affinity subset in CT3-preprimed,
G32CT3-immunized mice could result from one of two alternate
possibilities. First, it may represent a minority component of the
total pool of G32CT3-activated B cells. In such a situation their
subsequent elimination, under normal circumstances, is probably
in an environment of intense interclonal competition for a limiting
pool of T cell help (17, 19). Consequently, CT3 prepriming may
ensure their survival and subsequent expansion by making avail-
able an increased (perhaps nonlimiting) pool of activated Th cells.
An alternate explanation may be sought in the possibility that the
higher affinity Ab-producing cells represent derivatives of a dis-
tinct lineage that Klinman and colleagues have earlier proposed to
be the exclusive GC-populating subset (11–13). If the latter ex-
planation eventually proves to be true, it is then presently unclear
why the G32CT3-induced subpopulation requires an increased
proportion of T cell help compared with that for the anti-PS1CT3
B cells for either its induction or sustenance.
It is clear, therefore, that CT3 prepriming exerts a qualitative
influence on the composition of early anti-G32CT3 B cells that are
either generated or permitted to survive, with its resultant effect on
the serum Ab profile. However, we have previously ruled out a
role for Ab at the level of either average affinity or isotype com-
position. Consequently, we infer that the primary determinant of
GC-seeding ability in the CT3-primed vs unprimed G32CT3-im-
munized mice must reside in qualitative differences in the early
Ag-induced B cells generated in the two cases.
The differential Th cell thresholds required for promoting GC
formation from early anti-PS1CT3- and anti-G32CT3-activated B
cells argues for a dynamic balance that is regulated by the range of
B cell affinities that is initially produced on first encounter with
Ag. Although the determinants of B cell affinities invoked by an
Ag remain elusive, we have previously proposed that thermody-
namic considerations, defined by the chemical composition of an
epitope, may apply (19). In addition, the relationship between the
affinity for Ag and the GC-seeding capacity of Ag-activated B cells
needs clarification. However, in light of the available related in-
formation in the literature, it is possible to offer a speculative
working hypothesis. Studies from both our laboratory (20) and
others (45) have indicated that the Ag-binding characteristics of
sIg receptors directly relates to the ability of a given B cell to
recruit T cell help. Although alternate explanations may ultimately
prevail, at the simplest level, affinity for Ag may dictate the extent
of Ag uptake and, as a result, the avidity of a cognate B cell-T cell
interaction by defining the density of ligand eventually presented.
Variability in T cell recruitment ability may also be expected to lead
to differences in the extent of activation of the B cell, particularly with
respect to cell surface expression of accessory molecules such as
LFA-1, ICAM-1, B7, CD40L, etc., whose presence has been shown
to be critical for B cells to seed GCs (1, 28, 46–50).
In summary, our results support the idea that qualitative differ-
ences in B cell priming can lead to Ag-dependent differences in the
extent of GC formation. While confirming earlier suggestions of
intrinsic differences in the nature of B cell clones that participate
in AFC and GC responses (15), they extend these findings by
identifying the operation of an affinity threshold as the discrimi-
natory criterion. In addition to emphasizing a role for Ag-activated
B cells, our data minimize the influence of qualitative differences
in the Ab that constitutes immune complexes deposited on FDCs
to seed the GC reaction. It will be of interest to determine the
generality of our findings in other systems. Further, the mechanism
by which affinity for Ag influences the GC-forming competency
and characteristics of B cells that successfully seed GCs remains to
be explored.
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